VEGFA and neoplasm: From pharmacodynamic perspective, the advantages of the combined therapy of brivanib and cetuximab may occur because it not only inhibits VEGF-induced angiogenesis of tumor cells, but also inhibits EGFR signaling pathways in parallel to further inhibit the proliferation of tumor cells [54].